Aug 7, 2026 | Conduits News, Edition 10
Introducing the 2026 Pilot Projects Awardees and newest KL2 scholar from the Clinical & Translational Science Award (CTSA) research initiatives! The CTSA Program at Mount Sinai provides funding for clinical and translational research initiatives led by...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Bilal Naved, PhD, is a Faculty (Instructor) and Schmidt AI Fellow at the Icahn School of Medicine at Mount Sinai. He is an MD/PhD physician scientist trainee in the Northwestern Medical Scientist Training Program (MSTP) with a PhD in Biomedical Engineering and...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Kimberly Souffront, PhD, RN, FNP-BC, FAAN, is an Associate Professor of Emergency Medicine and Health Equity Science at the Icahn School of Medicine at Mount Sinai and Associate Director of the Center for Nursing Research and Innovation at the Mount Sinai Health...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Yun-Soung Kim, PhD, is an Assistant Professor of Radiology at the BioMedical Engineering and Imaging Institute of the Icahn School of Medicine at Mount Sinai. His research centers on bridging engineered materials with human physiology to enable clinically...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Anuradha Lala-Trinadade, MD, and her team are developing SheAligned, a non-invasive, multimodal wearable platform designed for perimenopausal women. It integrates biosensing (e.g., skin temperature, heart rate variability, respiration, sleep, and sweat-based...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Benjamin Kummer, MD, and his team, SeizAI, are using artificial intelligence to analyze smartphone videos of seizure-like episodes and distinguish epileptic seizures from functional dissociative seizures. Built on a validated machine learning model, the platform...
Aug 7, 2026 | Conduits News, Edition 10, Pilot Project Awardees
Dr. Jaime Hook, MD, and her team, Aerosome Therapeutics, are using Aerosome-01 to target ARDS, a large, underserved market with over 200,000 U.S. cases annually, 30-45% mortality, and no FDA-approved disease-modifying therapies. Aerosome-01 is an inhaled mRNA lipid...
Aug 7, 2026 | Conduits News, Edition 10, Trainee Corner
Dr. Myvizhi Selvan, PhD, is an Instructor at the Department of Genetics at the Icahn School of Medicine at Mount Sinai and the Thoracic Oncology Center at the NCI-designated Tisch Cancer Center at the Mount Sinai Health System. She is a computational scientist focused...